05:29am Wednesday 23 October 2019

Gout Flares Reduced with Protein-trapping Treatment

Now, these painful gout attacks may be preventable. Using a drug shown to substantially reduce gout flares, new research performed at the Perelman School of Medicine at the University of Pennsylvania and published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), showed that rilonacept effectively halts the cascade of events leading to these flare-ups, compared with placebo, by acting as a decoy to attract and then trap the pro-inflammatory cytokine interleukin-1 (IL-1).

This is the first study to demonstrate an effective prophylactic treatment to prevent acute gout flares during initiation of urate-lowering therapy.

In a randomized, double-blind, placebo-controlled Phase II trial, there were significantly fewer gout flares (6 flares on rilonacept, 33 flares on placebo) and a significantly lower percentage of patients with flares on rilonacept compared with placebo (15 percent  vs 45 percent).

“This trial provides well-controlled evidence that this IL-1 blocker is effective in preventing acute gout flares in this setting,” said the study’s lead author, H. Ralph Schumacher, Jr., MD, professor of Medicine in Rheumatology with the Perelman School of Medicine at the University of Pennsylvania.

The study was sponsored by Regeneron Pharmaceuticals, Inc, the maker of rilonacept. Dr. Schumacher has received consulting fees from Regeneron, Takeda, Savient, Ardea, Pfizer, Xoma, and Novartis.

For more information on the study, see the Arthritis & Rheumatism press release.



Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $4 billion enterprise.

Penn’s Perelman School of Medicine is currently ranked #2 in U.S. News & World Report’s survey of research-oriented medical schools and among the top 10 schools for primary care. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $507.6 million awarded in the 2010 fiscal year.

The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania — recognized as one of the nation’s top 10 hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital – the nation’s first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2010, Penn Medicine provided $788 million to benefit our community.


Share on:

Health news